Preparation of peptide and protein powders for inhalation

Advanced Drug Delivery Reviews

Volumn 26, Issue 1, 1997, Pages 3-15

  Johnson, Keith A ^a,b  

^a NEKTAR THERAPEUTICS   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Macromolecules; Manufacturing; Peptides; Powder; Production; Proteins

Indexed keywords

ABSORPTION; AEROSOLS; BIOLOGY; BIOTECHNOLOGY; DRUG DOSAGE; DRUG PRODUCTS; MACROMOLECULES; POWDERS; PROTEINS; PULMONARY DISEASES; RESPIRATORY THERAPY; TISSUE;

BIOPHARMACEUTICALS; PEPTIDES;

CONTROLLED DRUG DELIVERY;

DRUG CARRIER; PEPTIDE; PROTEIN;

ADULT RESPIRATORY DISTRESS SYNDROME; AEROSOL; ARTICLE; ASTHMA; BREATHING DISORDER; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; INHALATION; LUNG EMPHYSEMA; PARTICLE SIZE; POWDER; PRIORITY JOURNAL;

EID: 0031560925     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(97)00506-1     Document Type: Review

References (90)

1. Bashoff, E.C. and Beaser, R.S. (1995) Insulin therapy and the reluctant patient. Overcoming obstacles to success. Postgrad. Med. 97, 86-90.
2. Weissberg-Benchell, J., Glasgow, A.M., Tynan, W.D., Wirtz, P., Turek J. and Ward, J. (1995) Adolescent diabetes management and mismanagement. Diabetes Care 18, 77-82.
3. Mackay, M., Phillips, J., Steward A. and Hastewell, J. (1994) Pulmonary absorption of therapeutic peptides and proteins. In: P.R. Byron, R.N. Dalby and S.J. Farr (Eds.), Respiratory Drug Delivery IV. Interpharm Press, Buffalo Grove, IL, pp. 31-37.
4. Schneeberger, E.E. (1978) Structural basis for some permeability properties of the air-blood barrier. Federation Proc. 37, 2471-2478.
5. Patton, J.S. Trinchero, P. and Platz, R.M. (1994) Bioavailability of pulmonary delivered peptides and proteins: α-interferon, calcitonins and parathyroid hormones. J. Control. Release 28, 79-85.
6. Niven, R.W. (1992) Modulated drug therapy with inhalation aerosols. In: A.J. Hickey (Ed.) Pharmaceutical Inhalation Aerosol Technology. Marcel Dekker, New York, pp. 321-359.
7. Fiel, S.B., Fuchs, H.J., Johnson, C., Gonda, I. and Clark, A.R. (1995) Comparison of three jet nebulizer aerosol delivery systems used to administer recombinant human DNase I to patients with cystic fibrosis. Chest 108, 153-156.
8. Roosdorp, N.J. and Crystal, R.G. (1988) Aersolization of protein therapeutic agent. European Patent Application 0 289 336 A2.
9. Hinds, W.C. (1982) Aerosol Technology. John Wiley and Sons, New York.
10. Gonda, I. (1992) Targeting by deposition. In: A.J. Hickey (Ed.) Pharmaceutical Inhalation Aerosol Technology. Marcel Dekker, New York, pp. 61-82.
11. Clark, A.R. and Hollingworth, A.M. (1993) The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers - implications for in vitro testing. J. Aerosol Med. 6, 99-110.
12. Farr, S.J., Rowe, A.M., Rubsamen, R. and Taylor, G. (1994) Optimisation of aerosol inhalation form metered dose inhalers by use of a novel microprocessor-controlled device. Pharm. Res. 11, S158.
13. Hickey, A.J. (1992) Approaches to pharmaceutical aerosol administration. In: A.J. Hickey (Ed.) Pharmaceutical Inhalation Aerosol Technology. Marcel Dekker, New York, pp. 263-268.
14. Sciarra, J.J., Patel, J.M. and Kapoor, A.L. (1972) Synthesis and formulation of several epinephrine salts as an aerosol dosage form. J. Pharm. Sci., 61, 219-223.
15. Vidgren, M., Kärkkäinen, A., Karjalainen, P., Paronen, P. and Nuutinen, J. (1988) Effect of powder inhaler design on drug deposition in the respiratory tract. Int. J. Pharm. 42, 211-216.
16. Timsina, M.P., Martin, G.P., Marriot, C., Ganderton, D. and Yianneskis, M. (1994) Drug delivery to the respiratory tract using dry powder inhalers. Int. J. Pharm. 101, 1-13.
17. Johnson, K.A. (1996) Interfacial phenomena and phase behavior in metered dose inhaler formulations. In: A.J. Hickey (Ed.) Inhalation aerosols: physical and biological basis for therapy. Marcel Dekker, New York, pp. 385-415.
18. Rees, P.J., Clark, T.J.H. and Morén, F. (1982) The importance of particle size in response to inhaled bronchodilators. Eur. J. Respir. Dis. Suppl. 119, 63, 73-78.
19. Cameron, D., Clay, M. and Silverman, M. (1990) Evaluation of nebulizer for use in neonatal ventilator circuits. Crit. Care Med. 18, 866-870.
20. Dalby R.N. and Tiano, S.L. (1994) Rational testing methods for nebulizers and respiratory solutions. In: P.R. Byron, R.N. Dalby and S.J. Farr (Eds.) Respiratory Drug Delivery IV. Interpharm. Press, Buffalo Grove, IL, pp. 249-257.
21. Johnson, M.A., Newman, S.P., Bloom, R., Talaee, N. and Clarke, S.W. (1989) Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma. Chest 96, 6-10.
22. Clarke, S.W. and Newman, S.P. (1987) Drug delivery to the lungs. In: J.D. Wilson (Ed.) Drug use in respiratory disease. Williams and Wilkins and Associates Pty, Artarmon, Australia, pp. 11-26.
23. F-D-C Reports (1996) March 18, T and G-2.
24. Tansey, I.P.(1994) Challenges in the development of metered dose inhaler aerosols using ozone friendly propellants. Spray Technol. Marketing 4, 26.
25. Newman, S.P., Weisz, A.W., Talaee, N. and Clarke, S.W. (1991) Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax 46, 712-716.
26. Davis, S.S., Hardy, J.G., Newman, S.P. and Wilding, I.R. (1992) Gamma scintigraphy in the evaluation of pharmaceutical dosage forms. Eur. J. Nuc. Med. 19, 971-986.
27. Kenyon, C.J., Dewsbury, N.J. and Newman, S.P. (1995) Differences in aerodynamic particle size distributions of innovator and generic beclomethasone dipropionate aerosol used with and without a large volume spacer. Thorax 50, 846-850.
28. Hindle, M., Jasnani, R.N. and Byron, P.R. (1994) Dose emissions from marketed inhalers: influence of flow, volume and environment. In: P.R. Byron, R.N. Dalby and S.J. Farr (Eds.) Respiratory Drug Delivery IV. Interpharm Press, Buffalo Grove, IL, pp. 137-142.
29. Bell, A. (1995) The dry powder inhaler. Conference sponsored by Management Forum, Guildford, England.
30. Hilder, R.C. and Barlow, D. (1991) Polypeptide and protein drugs: production, characterization and formulation. Ellis Harwood, Chichester, England.
31. Geigert, J. (1989) Overview of the stability and handling of recombinant protein drugs. J. Parenteral Sci. Tech. 43, 220-224.
32. Wang, Y.J. and Hanson, M.A. (1988) Parentaral formulations of proteins and peptides: stability and stabilizers. J. Parenteral Sci. Tech. 42, S3-S26.
33. Manning, M.C., Patel, K. and Borchardt, R. (1989) Stability of protein pharmaceuticals. Pharm. Res. 6, 903-918.
34. Pace, C.N. 1990) Measuring and increasing protein stability. TIBTECH 8, 93-98.
35. Pearlman, R. and Nguyen, T. (1992) Pharmaceutics of protein drugs. J. Pharm. Pharmacol. 44, 178-185.
36. Li, S., Schöneich, C. and Borchardt, R.T. (1995) Chemical instability of proteins. Pharmaceutical News 2, 12-16.
37. Franks, F. (1993) Storage stabilization of proteins. In F. Franks (Ed.) Protein biotechnology: isolation, characterization and stabilization. The Humana Press, Totowa, New Jersey, pp. 491-498.
38. Dörr, F. (1983) Structure determination of biomolecules by physical methods. In: W. Hoppe, W. Lohmann, H. Markl and H. Ziegler (Eds.) Biophysics. Springer-Verlag, Berlin, p. 58.
39. Cantor, C.R. and Schimmel, P.R. (1980) Biophysical chemistry part II: techniques for the study of biological structure and function. W.H. Freeman, San Francisco, pp. 764-765.
40. Franks, F. (1993) Storage stabilization of proteins. In F. Franks (Ed.) Protein biotechnology: isolation, characterization and stabilization. The Humana Press, Totowa, New Jersey, p. 490.
41. Levine, H. and Slade, L. (1988) Principles of cryostabilization technology from structure/property relationships of carbohydrate/water systems. Cryo-letters 9, 21-63.
42. Fox, K.C. (1995) Putting proteins under glass. Science 267, 1922-1923.
43. Franks, F. and Hately, R.H.M. (1992) Storage of materials. US Patent 5098 893.
44. Pikal, M.J. (1990) Freeze-drying of proteins part II: formulation selection. Biopharm. 10, 26-30.
45. Angell, C.A. (1995) Formation of glasses from liquids and biopolymers. Science 267, 1924-1935.
46. Pikal, M.J. (1990) Freeze-drying of proteins part I: process design. Biopharm. 9, 18-27.
47. Roser, B.J. (1990) Protection of proteins and the like. US Patent 4891 319.
48. Tucker, J.D. and Parker, J.W. (1990) Global considerations in the development and production of pharmaceuticals. In: C.E. Hamner (Ed.) Drug Development. CRC Press, Boca Raton, p. 286-288.
49. Liu, W.R., Langer, R. and Klibanov, A.M. (1991) Moisture-induced aggregation of lyophilized proteins in the solid state. Biotech. Bioeng. 37, 177-184.
50. Ackers, M.J. and Nail, S.L. (1994) Top 10 current technical issues in parenteral science. Pharm. Technol. 18, 26-36.
51. Clark, A.R. and Hollingworth, A.M. (1993) Pharmaceutical composition. US patent 5198 221.
52. Hallworth, G.W. (1987) The formulation and evaluation of pressurised metered-dose inhalers. In: D. Ganderton and T.M. Jones (Eds.) Drug delivery to the respiratory tract. Ellis Horwood, Chichester, England, pp. 87-118.
53. Snow, R.H., Kaye, B.H., Capes, C.E. and Sresty, G.C. (1984) Size reduction and size enlargement. In: R.H. Perry and D. Green (Eds.) Perry's Chemical Engineer's Handbook. McGraw Hill, New York, Ch. 8, pp. 1-59.
54. Carstensen, J.T. (1993) Pharmaceutical principles of solid dosage forms. Technomic Publishing, Basel, pp. 47-52.
55. Van Vlack, L.H. (1980) Elements of materials science and engineering. Addison Wesley Publishing, Reading, MA, pp. 185-208.
56. Tomihisa, K. (1973) Grinding of rubber below the brittle temperature with supersonic jet air. Japanese patent JP 73103 614.
57. Ogura K. and Sobue, H. (1970) Changes in morphology with milling of the commercial microcrystalline cellulose. J. App. Polymer Sci. 14, 1390-1393.
58. Ward, G.H. and Schultz, R.K. (1995) Process-induced crystallinity changes in albuterol sulfate and its effect on powder physical stability. Pharm. Res. 12, 773-779.
59. Kaneniwa, N. and Ikekawa, A. (1972) Influence of ball-milling atmosphere on decrease of molecular weight of polyvinylpyrrolidone powders. Chem. Pharm. Bull. 20, 1536-1543.
60. Adjei, A. (1990) Pulmonary bioavailablility of peptide drugs: animal models, preclinical studies and clinical studies. Presented at Respiratory Drug Delivery II, Keystone, CO.
61. Adjei, A., Sundberg, D., Miller, J. and Chun, A. (1992) Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. Pharm. Res. 9, 244-249.
62. Bäckström, K.G., Dahlbäck, C.M., Edman, P. and Johansson, A.C.B. (1995) Therapeutic preparation for inhalation. International patent application WO 95/00127.
63. Platz, R.M., Ip, A. and Whitham, C.L. (1994) Process for preparing micronized polypeptide drugs. US Patent 5354 562.
64. Platz, R.M., Utsumi, J., Satoh, Y. and Naruse, N. (1991) Pharmaceutical aerosol formulation of solid polypeptide microparticles and method for the preparation thereof. International patent application number WO 91/16 038.
65. Kobayashi, S., Kondo, S. and Juni, K. (1996) Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats. Pharm. Res. 13, 80-83.
66. Gombotz, W.R., Healy, M.S., Brown, L.R. and Auer, H.E. (1994) Process for producing small particles of biologically active molecules. European patent application EP 0 432 232 B 1.
67. Forrester, R.B. and Boardman, T.D. (1986) Inhalation pharmaceuticals. US Patent 4590 206.
68. Durrani, M., Fitch, W., Fok, K., Radhakrishnan, R. and Uster, P.S. (1991) Direct spray-dried drug/lipid powder composition. International patent application WO 91/16 882.
69. Naini, Y, Byron, P.R. and Phillips, E.M. (1995) Physical characterization of spray dried sugars suitable as carriers in inhalation systems. Presented at the American Association of Pharmaceutical Scientists Meeting, PT6180.
70. Masters, K. (1991) Spray Drying Handbook. Longman Scientific and Technical, Essex, England.
71. Mumenthaler, M., Hsu, C.C. and Pearlman, R. (1994) Feasibility study on spray-drying protein pharmaceuticals: recombinant human growth hormone and tissue-type plasminogen activator. Pharm. Res. 11, 12-20.
72. Broadhead, J., Rouan, S.K.E., Hau, I. and Rhodes, C.T. (1994) The effect of process and formulation variable on the properties of spray dried β-galactosidase. J. Pharm. Pharmacol. 46, 458-467.
73. Alexander, K. and King, C.J. (1985) Factors governing surface morphology of spray-dried amorphous substances. Drying Tech. 3, 321-348.
74. Patton, J.S., Foster, L.C. and Platz, R.M. (1995) Methods and composition for pulmonary delivery of insulin. International patent application WO 95/24 183.
75. Niven, R.W., Lott, F.D., Ip, A.Y. and Cribbs, J.M. (1994) Pulmonary delivery of powders and solutions containing recombinant human granulocyte colony-stimulating factor. Pharm. Res. 11, 1101-1109.
76. Dalby, R.N., Naini, V. and Byron, P.R. (1992) Droplet drying and electrostatic collection, a novel alternative to conventional comminution techniques. J. Biopharm. Sci. 3, 91-99.
77. Sutton, A.D., Johnson, R.A., Senior, P.J. and Heath, D. (1995) Preparation of diagnostic agents. European patent application 0 681 843 A2
78. Gallagher-Wetmore, P. Coffey, M.P and Krukonis, V. (1994) Recrystallization using supercritical fluids: novel techniques for particle modification. Presented at the First International Particle Technology Forum, Denver.
79. Prausnitz, J.M. (1969) Molecular thermodynamics of fluid-phase equilibria. Prentice-Hall, New Jersey, pp. 407-452.
80. Mullin, J.W. (1993) Crystallization. Butterworth-Heinemann, Oxford, pp. 272-273.
81. McHugh, M.A. and Krukonis, V. (1994) Supercritical fluid extraction. Butterworth-Heinemann, Boston.
82. Reid, R.C., Prausnitz, J.M. and Poling, B.E. (1986) The properties of gases and liquids. McGraw Hill, New York, p. 667.
83. Debenedetti, P.G., Lim, G. and Prud'Homme, R.K. (1993) Formation of protein microparticles by antisolvent precipitation. European patent application EP 0 542 314 A1.
84. Yeo, S., Lim, G., Debenedetti, PG. and Bernestein, H. (1993) Formation of microparticulate protein powders using a supercritical fluid antisolvent. Biotechnol. Bioeng. 41, 341-346.
85. Singer, N.S., Yamamoto, S. and Latella, J. (1988) Protein product base. US Patent 4734 287.
86. Hastings, D.H. (1991) Method of producing antibody-fortified dry whey. US Patent 5017 372.
87. Brown, K. (1987) The formulation and evaluation of powders for inhalation. In: D. Ganderton and T. Jones (Eds.) Drug delivery to the respiratory tract. Ellis Horwood, Chichester, pp. 119-123.
88. Ganderton, D. and Kassem, N.M. (1993) Aerosol carriers. US Patent 5254 330.
89. Yanagawa, A. (1995) Physiologically active peptide compositions. European patent application 0 648 498 A1.
90. Yanagawa, A. and Noriyuki, S. (1993) Physiologically active peptide compositions. European patent application 0 588 255 A1.